2018
DOI: 10.5897/ajpp2018.4942
|View full text |Cite
|
Sign up to set email alerts
|

Plasmodium falciparum drug resistance gene status in the Horn of Africa: A systematic review

Abstract: Antimalarial drug resistance monitoring is the key factor in malaria control policy for early detection and subsequent prevention of drug resistance spread. This review was performed to collate all available data of P. falciparum resistant genes in the Horn of Africa as a baseline for future appraisal of the regional malaria control policy. The search of this review was performed in January 2018 using the scientific databases Pub Med and Google Scholar. The search terms used included: Plasmodium falciparum AND… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

0
5
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
3
3

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(5 citation statements)
references
References 37 publications
(91 reference statements)
0
5
0
Order By: Relevance
“…Commercial slide scanning and detection systems show promise [26, 27] but are currently expensive. With persisting high burden of malaria [28] and the rise of drug resistance strains [29, 30, 31], affordable, high-throughput and quantitative diagnostic tests are urgently needed.…”
Section: Introductionmentioning
confidence: 99%
“…Commercial slide scanning and detection systems show promise [26, 27] but are currently expensive. With persisting high burden of malaria [28] and the rise of drug resistance strains [29, 30, 31], affordable, high-throughput and quantitative diagnostic tests are urgently needed.…”
Section: Introductionmentioning
confidence: 99%
“…Across malaria-endemic regions, large-scale deployment of anti-malarial drugs has led to the emergence of drug resistance to chloroquine (CQ) and sulfadoxine/pyrimethamine (SP) antifolate drugs [ 3 5 ]. Like many other countries, Ethiopia has switched from CQ to SP in 1998 and from SP to artemether–lumefantrine (AL) in 2004 [ 6 ] for the treatment of uncomplicated P. falciparum malaria in response to the development of parasite resistance.…”
Section: Introductionmentioning
confidence: 99%
“…Across malaria-endemic regions, large-scale deployment of antimalarial drugs has led to the emergence of drug resistance to chloroquine (CQ) and Sulfadoxine/Pyrimethamine (SP) antifolate drugs [3][4][5]. Like many other countries, Ethiopia has switched from CQ to SP in 1998 and from SP to AL in 2004 [6]for the treatment of uncomplicated P. falciparum malaria in response to the development of parasite resistance.…”
Section: Introductionmentioning
confidence: 99%